Oppenheimer analyst Leland Gershell lowered the firm’s price target on Argenx (ARGX) to $1,014 from $1,060 and keeps an Outperform rating on the shares. The firm made a variety of adjustments to its Argenx model. Oppenheimer now projects 2026-2030 total revenue of $6.05B, 7.95B, 9.98B, 12.68B, and 16.04B vs. prior $6.50B, 8.02B, 10.07B, 12.77B, and 16.14B, respectively.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx added to European Conviction List at Goldman Sachs
- Argenx Sets May 6, 2026 AGM and Unveils Board Changes as Jim Daly Retires
- Argenx Files 2025 Annual Report and Links Dutch Filing to U.S. Registrations
- Argenx Halts Phase 3 Thyroid Eye Disease Trial: Clinical Setback With Focused Market Impact
- Argenx Ends Phase 3 Thyroid Eye Disease Trial, Resetting Expectations for Efgartigimod